(Albany, US) DelveInsight has launched a new report on Acute on Chronic Liver Failure Market
DelveInsight’s “Acute On Chronic Liver Failure (ACLF) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acute On Chronic Liver Failure (ACLF) , historical and forecasted epidemiology as well as the Acute On Chronic Liver Failure (ACLF) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Acute On Chronic Liver Failure (ACLF) market report provides current treatment practices, emerging drugs, Acute On Chronic Liver Failure (ACLF) market share of the individual therapies, current and forecasted Acute On Chronic Liver Failure (ACLF) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acute on Chronic Liver Failure (ACLF) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
The term Acute-on-Chronic Liver Failure (ACLF) was first introduced in 1995 to describe a condition in which two “lesions” or “insults” act simultaneously on the liver, one of which is chronic and the other is acute. However, the universally accepted and used definition of ACLF is still lacking. Thus, several definitions have been developed by expert groups from the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Asian-Pacific Association for the Study of the Liver (APASL). According to AASLD and EASL working group ACLF is, “Acute deterioration of pre-existing chronic liver disease usually related to a precipitating event and associated with increased mortality at 3-months due to multi-system organ failure”. On the other hand, the group of experts from APASL define the ACLF as, “Acute liver injury manifesting as jaundice (serum bilirubin ≥5 mg/dL) and coagulopathy (INR ≥1.5 or prothrombin activity of <40%), complicated within 4 weeks by ascites and/or encephalopathy in a patient previously diagnosed or undiagnosed chronic liver diseases.”
Click here for Free sample page:- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
Acute on Chronic Liver Failure Market
Currently, there is no specific effective treatment available for patients with ACLF, and therefore, treatment is based on organ support and treatment of associated complications. Central to the treatment of ACLF is early diagnosis and control of the precipitating factor. The main principles of management in these patients are to provide support to each of the organs with failure and to promote recovery of the hepatic gland. The current treatment includes the use of Devices for detoxification, Antiviral therapy and Liver transplantation.
Acute on Chronic Liver Failure Treatment
Moreover, due to its multifactorial nature, a single therapeutic action would not be effective in reversing the disease. Considering that currently there is no specific treatment for ACLF, research should be based on potential new treatments addressed to pathophysiological mechanisms. To fulfill the current unmet need, the field of ACLF has moved very rapidly in the past 5 years. The availability of a large volume of published data from the East and the West has allowed reassessing the initial definitions. And attempts to abrogate, ameliorate, or reverse the ongoing injury would allow the return of hepatic synthetic functions and reversal of the liver damage. Early predictors of mortality and non-reversibility of the condition would pave the way to offer priority liver transplantation to such patients.
Acute on Chronic Liver Failure Report Scope
Download free sample page:- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
Table of content
1. Key Insights
2. Executive Summary of Acute On Chronic Liver Failure (ACLF)
3. Competitive Intelligence Analysis for Acute On Chronic Liver Failure (ACLF)
4. Acute On Chronic Liver Failure (ACLF): Market Overview at a Glance
5. Acute On Chronic Liver Failure (ACLF): Disease Background and Overview
6. Patient Journey
7. Acute On Chronic Liver Failure (ACLF) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Acute On Chronic Liver Failure (ACLF) Treatment
11. Marketed Products
12. Emerging Therapies
13. Acute On Chronic Liver Failure (ACLF): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Acute On Chronic Liver Failure (ACLF)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
Related Reports
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/